DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Study DC-6001-101 is a multicenter, open-label, Phase 1 study to assess the effects of
anti-CD93 mAbs as a monotherapy in patients with advanced or metastatic solid tumors. The
study comprises Part A (compound DCBY02) and Part B (compound DCSZ11, not yet active).